Skip to main content

Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low226.80
Day High231.60
Open:230.36
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Abbvie Inc

Select a category then submit the form to load news
Zacks Investment Research
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
Tipranks
J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
StockStory
AbbVie (ABBV): Buy, Sell, or Hold Post Q4 Earnings?
ABBV
Tipranks
AbbVie Completes $8 Billion Senior Notes Financing Offering
Tipranks
AbbVie Advances Venetoclax Into Rare Blood Cancers With New Phase 2 Study
Motley Fool
AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell
Tipranks
Analysts’ Top Healthcare Picks: Zymeworks (ZYME), AbbVie (ABBV)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Butterfly Network (BFLY) and Disc Medicine (IRON)
Motley Fool
Why AbbVie Stock May Be the Ultimate Option for Dividend Investors
Tipranks
AbbVie Announces $7.5 Billion Senior Notes Offering
Motley Fool
Where Will AbbVie Be in 5 Years?
Tipranks
DBS Sticks to Their Hold Rating for AbbVie (ABBV)
Tipranks
AbbVie’s Real‑World Vraylar Study in Bipolar I Disorder Reaches Completion
Motley Fool
This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
Zacks Investment Research
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
StockStory
1 Cash-Producing Stock to Target This Week and 2 We Ignore
DBX
Tipranks
AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142
Zacks Investment Research
Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?
Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?
Motley Fool
3 Stocks to Buy and Hold for 2026 and Beyond
Tipranks
AbbVie’s VOLITE Skin Quality Trial Completion: What It Means for ABBV Investors
Tipranks
AbbVie’s ABBV-547 First‑in‑Human Trial: What Early Pipeline Moves Mean for ABBV Investors
Motley Fool
2 Dividend Stocks to Hold for the Next 5 Years
Motley Fool
6 Forever Dividend Stocks
StockStory
1 Mega-Cap Stock on Our Watchlist and 2 We Avoid
ABBV
Motley Fool
8 Cheap Stocks to Buy in 2026
Motley Fool
1 No-Brainer Dividend Stock to Buy on the Dip
Motley Fool
5 Best Stocks to Buy in February
Motley Fool
3 Dividend Stocks to Hold for the Next 20 Years
Tipranks
AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch
Motley Fool
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Motley Fool
Got $500? 2 Pharma Stocks to Buy and Hold Forever.

Profile

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.